ZYLOPRIM is indicated in:
1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks,
tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer
therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should
be discontinued when the potential for overproduction of uric acid is no longer present.
3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion
exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should
be carefully assessed initially and reassessed periodically to determine in each case that treatment is
beneficial and that the benefits outweigh the risks.
